Imatinib mesylate CAS NO.220127-57-1

We have been providing over 1000 products including molecular targeted anticancer drugs, cell signaling pathway

inhibitors, pharmaceutical intermediates, and heterocyclic compounds, and quality services including custom

synthesis, transfer of new drug patent and technology, technical cooperation, and process optimization.

Jinan Trio PharmaTech was founded by a core group of top overseas pharmaceutical chemists, Medical scientists and

business management experts, and is an enterprise of science and technology supported by the "Attracting High-

Level Talent Scheme" of Jinan government.

Jinan Trio PharmaTech Co., Ltd. 

Year Establishment: 2008

Location: We are located at one of the largest National Technical Integrated Drug Discovery Platforms in the High-Tech Zone of Jinan City

Our company was founded by a core group of top overseas pharmaceutical chemists, medical scientists business

management experts

We have built up solid cooperation with over twenty oversea companies over one hundred domestic companies

since the foundation

Specifications:

Name  Imatinib mesylate

Synonyms  4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide

monomethanesulfonate; STI-571

Molecular Formula  C₂₉H₃₁N₇O.CH₄O₃S

Molecular Weight  589.71

CAS Registry Number  220127-57-1
 

Applications:

Imatinib Mesylate is orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with

IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively. Imatinib also known as Gleevec, Glivec, CGP-57148B, STI-571 & Imatinib